Inmed appoints dr. david g. morgan, phd, a leading alzheimer's expert, to the company's scientific advisory board

Vancouver, british columbia--(newsfile corp. - april 18, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the addition of dr. david g. morgan, a renowned leader in neurodegenerative disease to its scientific advisory board ("sab") reinforcing the company's commitment to advancing it's inm-901 program in the treatment of alzheimer's disease.
INM Ratings Summary
INM Quant Ranking